This study aims to determine whether antiviral or other drugs can help people who have COVID symptoms that have lasted more than 3 months after a COVID infection, a condition known as post-acute sequelae of SARS-CoV-2 infection, including long COVID. Participants will be randomly assigned to 1 of 2 groups. One group will receive Paxlovid, a combination of 2 nirmatrelvir pills and 1 ritonavir pill. The other group (control group) will receive a combination of 2 placebo pills (inactive substance) and 1 ritonavir pill. Researchers will study the effects that Paxlovid may have on patients’ ability to recover from long COVID. The use of Paxlovid, nirmatrelvir and ritonavir is considered investigational in this study.
What is the full name of this clinical trial?
RECOVER-VITAL: A Platform Protocol for Evaluation of Interventions for Viral Persistence, Viral Reactivation, and Immune Dysregulation in Post-Acute Sequelae of SARS-CoV-2 Infection